Plain Language Summary 152.pptx (428.98 kB)View fileThis item contains files with download restrictions
Next page
Previous page
1/1
Switch ViewSwitch between different file views
Thumbnail viewList viewFile view
2 filesFullscreen
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis
Version 2 2023-02-15, 00:18Version 2 2023-02-15, 00:18
Version 1 2022-12-18, 19:28Version 1 2022-12-18, 19:28
media
posted on 2022-12-18, 19:28authored byAdis Journals on behalf of:, Amy S. Paller, Elaine C Siegfried, Michael J. Cork, Andreas Wollenberg, Peter D. Arkwright, Mercedes E. Gonzalez, Benjamin Lockshin, Zhen Chen, Ashish Bansal, Noah A. Levit, Randy Prescilla
The above Key Points and Plain Language Summary represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite).